Cardiovascular Risks Associated With Celecoxib and Rofecoxib Dose/Drugs
| Authors | Dose/Trial Drug | Risk | Indication |
| bid = twice a day; qd = every day; CI = confidence interval; HR = hazard ratio; OR = odds ratio; RR = relative risk. | |||
| [40] | Rofecoxib <25 mg/qd; rofecoxib >25 mg/qd | OR = 1.47 (0.99–2.17) 3 vs. 58 (1.27–10.17) | Nested case-control study all users |
| [42] | Celecoxib 200 mg/qd vs. 400 mg bid | 3.4%; HR = 3.4 (95% CI, 1.4–7.8) | Sporadic adenoma prevention trial (N = 2,035) |
| [41] | Rofecoxib 25 mg/qd | RR = 1.92 (95% CI, 1.19–3.11; P = .008) | Chemoprevention sporadic adenoma |
| [39] | Rofecoxib 25 mg/qd | RR (estimated) = 2.66 (95% CI, 1.03–6.86; P = .04) | Chemoprevention sporadic adenoma median study Rx 7.4 months |
References
- Kerr DJ, Dunn JA, Langman MJ, et al.: Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 357 (4): 360-9, 2007. [PUBMED Abstract]
- Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (9458): 475-81, 2005. [PUBMED Abstract]
- Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (11): 1092-102, 2005. [PUBMED Abstract]
- Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (11): 1071-80, 2005. [PUBMED Abstract]
